CAPS Rating: 2 out of 5

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.


Player Avatar TSIF (99.96) Submitted: 6/19/2012 9:05:28 AM : Underperform Start Price: $7.27 DNDNQ Score: +15.24

No reason for a 20% upspike on Dendreon other than someone thought it got "too cheap" and shorts had to do some covering. I can't find any fundamentals that would suggest Dendreon share price should increase from here. Although it's Provenge is a worthy achievement, as expected it couldn't productize it and it never got the buyout it sought. One trick pony with a drug that's expensive, difficult to manufacture and difficult to get doctors to prescribe. Burn rate continues with no end in sight. Short term CAPS play, will not ride it down too far.

Featured Broker Partners